Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.52 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32687995 | 0.85 | POLB (0.46) | KDM4ERECQLTDP1 | |
| SCHEMBL32688076 | 0.83 | KDM4E (0.50) | ACMSDKDM4ERECQLTDP1ATM | |
| SCHEMBL20339404 | 0.83 | ATM (0.58) | KDM4ERECQLTDP1ATM | |
| SCHEMBL32688045 | 0.82 | ACMSD (0.46) | ACMSDKDM4ERECQLTDP1ATM | |
| SCHEMBL20340038 | 0.80 | KDM4E (0.56) | KDM4ERECQLTDP1ATM | |
| SCHEMBL32688165 | 0.76 | KDM4E (0.48) | IKBKBKDM4ERECQLTDP1ATM | |
| SCHEMBL20350824 | 0.76 | KDM4E (0.50) | IKBKBKDM4ERECQLTDP1 | |
| SCHEMBL32688273 | 0.75 | KDM4E (0.44) | KDM4ERECQLTDP1ATM | |
| SCHEMBL32688129 | 0.75 | KDM4E (0.42) | KDM4ERECQLTDP1ATM | |
| SCHEMBL32688304 | 0.74 | KDM4E (0.47) | KDM4ERECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | ORSOBIO INC (US) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | CPT1B, CBR1, MUSK | ACMSD 142/4885IKBKB 902/4885KDM4E 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.